1079 related articles for article (PubMed ID: 8542596)
21. Enhancement of membrane-type 1-matrix metalloproteinase (MT1-MMP) production and sequential activation of progelatinase A on human squamous carcinoma cells co-cultured with human dermal fibroblasts.
Sato T; Iwai M; Sakai T; Sato H; Seiki M; Mori Y; Ito A
Br J Cancer; 1999 Jun; 80(8):1137-43. PubMed ID: 10376963
[TBL] [Abstract][Full Text] [Related]
22. Plasma membrane-dependent activation of gelatinase A in human vascular endothelial cells.
Lewalle JM; Munaut C; Pichot B; Cataldo D; Baramova E; Foidart JM
J Cell Physiol; 1995 Dec; 165(3):475-83. PubMed ID: 7593226
[TBL] [Abstract][Full Text] [Related]
23. Expression of membrane-type 1 matrix metalloproteinase and activation of progelatinase A in human osteoarthritic cartilage.
Imai K; Ohta S; Matsumoto T; Fujimoto N; Sato H; Seiki M; Okada Y
Am J Pathol; 1997 Jul; 151(1):245-56. PubMed ID: 9212749
[TBL] [Abstract][Full Text] [Related]
24. Independent regulation of matrix metalloproteinases and plasminogen activators in human fibrosarcoma cells.
Lim YT; Sugiura Y; Laug WE; Sun B; Garcia A; DeClerck YA
J Cell Physiol; 1996 May; 167(2):333-40. PubMed ID: 8613475
[TBL] [Abstract][Full Text] [Related]
25. Activation of human umbilical vein endothelial cell progelatinase A by phorbol myristate acetate: a protein kinase C-dependent mechanism involving a membrane-type matrix metalloproteinase.
Foda HD; George S; Conner C; Drews M; Tompkins DC; Zucker S
Lab Invest; 1996 Feb; 74(2):538-45. PubMed ID: 8780171
[TBL] [Abstract][Full Text] [Related]
26. Tissue inhibitor of metalloproteinases-4 inhibits but does not support the activation of gelatinase A via efficient inhibition of membrane type 1-matrix metalloproteinase.
Bigg HF; Morrison CJ; Butler GS; Bogoyevitch MA; Wang Z; Soloway PD; Overall CM
Cancer Res; 2001 May; 61(9):3610-8. PubMed ID: 11325829
[TBL] [Abstract][Full Text] [Related]
27. Downregulation of MMP-9 in ERK-mutated stable transfectants inhibits glioma invasion in vitro.
Lakka SS; Jasti SL; Gondi C; Boyd D; Chandrasekar N; Dinh DH; Olivero WC; Gujrati M; Rao JS
Oncogene; 2002 Aug; 21(36):5601-8. PubMed ID: 12165859
[TBL] [Abstract][Full Text] [Related]
28. The influence of sequential, in vitro passage on secretion of matrix metalloproteinases by human brain tumour cells.
Rossi M; Rooprai HK; Maidment SL; Rucklidge GJ; Pilkington GJ
Anticancer Res; 1996; 16(1):121-8. PubMed ID: 8615596
[TBL] [Abstract][Full Text] [Related]
29. Clinical significance of expression of membrane type 1 matrix metalloproteinase and matrix metalloproteinase-2 in human head and neck squamous cell carcinoma.
Imanishi Y; Fujii M; Tokumaru Y; Tomita T; Kanke M; Kanzaki J; Kameyama K; Otani Y; Sato H
Hum Pathol; 2000 Aug; 31(8):895-904. PubMed ID: 10987249
[TBL] [Abstract][Full Text] [Related]
30. Roles of membrane type 1 matrix metalloproteinase and tissue inhibitor of metalloproteinases 2 in invasion and dissemination of human malignant glioma.
Nakada M; Kita D; Futami K; Yamashita J; Fujimoto N; Sato H; Okada Y
J Neurosurg; 2001 Mar; 94(3):464-73. PubMed ID: 11235952
[TBL] [Abstract][Full Text] [Related]
31. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis.
Määttä M; Soini Y; Liakka A; Autio-Harmainen H
Clin Cancer Res; 2000 Jul; 6(7):2726-34. PubMed ID: 10914717
[TBL] [Abstract][Full Text] [Related]
32. Carbohydrate-mediated regulation of matrix metalloproteinase-2 activation in normal human fibroblasts and fibrosarcoma cells.
Gervasi DC; Raz A; Dehem M; Yang M; Kurkinen M; Fridman R
Biochem Biophys Res Commun; 1996 Nov; 228(2):530-8. PubMed ID: 8920947
[TBL] [Abstract][Full Text] [Related]
33. Matrix metalloproteinases in human gliomas: activation of matrix metalloproteinase-2 (MMP-2) may be correlated with membrane-type-1 matrix metalloproteinase (MT1-MMP) expression.
Hur JH; Park MJ; Park IC; Yi DH; Rhee CH; Hong SI; Lee SH
J Korean Med Sci; 2000 Jun; 15(3):309-14. PubMed ID: 10895974
[TBL] [Abstract][Full Text] [Related]
34. Up-regulation of vascular endothelial growth factor by membrane-type 1 matrix metalloproteinase stimulates human glioma xenograft growth and angiogenesis.
Deryugina EI; Soroceanu L; Strongin AY
Cancer Res; 2002 Jan; 62(2):580-8. PubMed ID: 11809713
[TBL] [Abstract][Full Text] [Related]
35. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes.
Ries C; Loher F; Zang C; Ismair MG; Petrides PE
Clin Cancer Res; 1999 May; 5(5):1115-24. PubMed ID: 10353746
[TBL] [Abstract][Full Text] [Related]
36. Membrane type I-matrix metalloproteinase-mediated degradation of type I collagen by oral squamous cell carcinoma cells.
Aznavoorian S; Moore BA; Alexander-Lister LD; Hallit SL; Windsor LJ; Engler JA
Cancer Res; 2001 Aug; 61(16):6264-75. PubMed ID: 11507081
[TBL] [Abstract][Full Text] [Related]
37. Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression and synthetic matrix metalloproteinase-2 inhibitor binding in ovarian carcinomas and tumor cell lines.
Afzal S; Lalani el-N ; Foulkes WD; Boyce B; Tickle S; Cardillo MR; Baker T; Pignatelli M; Stamp GW
Lab Invest; 1996 Feb; 74(2):406-21. PubMed ID: 8780160
[TBL] [Abstract][Full Text] [Related]
38. Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2).
Fridman R; Toth M; Peña D; Mobashery S
Cancer Res; 1995 Jun; 55(12):2548-55. PubMed ID: 7780967
[TBL] [Abstract][Full Text] [Related]
39. Patterns of expression of metalloproteinases and their inhibitors in human malignant lymphomas.
Kossakowska AE; Urbanski SJ; Watson A; Hayden LJ; Edwards DR
Oncol Res; 1993; 5(1):19-28. PubMed ID: 8369572
[TBL] [Abstract][Full Text] [Related]
40. Activation of the precursor of gelatinase A/72 kDa type IV collagenase/MMP-2 in lung carcinomas correlates with the expression of membrane-type matrix metalloproteinase (MT-MMP) and with lymph node metastasis.
Tokuraku M; Sato H; Murakami S; Okada Y; Watanabe Y; Seiki M
Int J Cancer; 1995 Oct; 64(5):355-9. PubMed ID: 7591310
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
